Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial
Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial
Chitapanarux et al., 2025 | Sci Rep | Rct
Citation
Chitapanarux Taned, Wiracha Umaporn, ... Traisathit Patrinee. Efficacy and safety of Saccharomyces boulardii as adjunct therapy with Vancomycin in treating Clostridioides difficile infection: A randomized controlled trial. Sci Rep. 2025-Jun-02;15(1):19326. doi:10.1038/s41598-025-04986-2
Abstract
Clostridioides difficile infection (CDI) is a significant cause of hospital-acquired diarrhea, leading to high morbidity, recurrence, and healthcare costs. Probiotics like Saccharomyces boulardii show potential as an adjunct therapy to standard CDI treatment, but further trials are needed to confirm their efficacy. This study assessed the efficacy and safety of S. boulardii combined with vancomycin for treating mild to moderate CDI. 120 CDI patients diagnosed with positive stool toxin test were randomly assigned to receive two capsules of 250 mg of S. boulardii or a placebo every 12 h alongside 125 mg of vancomycin every 6 h for 10 days. The primary endpoint was the clinical cure rate, with secondary endpoints including recurrence, global cure rate, and diarrheal outcomes. Clinical cure rates were similar between groups (98.4% vs. 98.3%), but the combination group had a significantly higher global cure rate (96.6% vs. 85.3%, p = 0.044) and lower recurrence rate (1.7% vs. 13.1%, p = 0.032). No significant differences were found in diarrheal outcomes, functional ability, or adverse events. No patients discontinued treatment due to intolerance. In conclusion, adding S. boulardii to vancomycin reduced CDI recurrence without affecting functional recovery or increasing adverse events.
Key Findings
boulardii to vancomycin reduced CDI recurrence without affecting functional recovery or increasing adverse events.
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | See abstract |
| Sample Size | See abstract |
| Age Range | See abstract |
| Condition | See abstract |
MeSH Terms
- Humans
- Vancomycin
- Saccharomyces boulardii
- Male
- Clostridium Infections
- Female
- Middle Aged
- Probiotics
- Aged
- Clostridioides difficile
- Adult
- Treatment Outcome
- Anti-Bacterial Agents
- Diarrhea
Evidence Classification
- Level: Rct
- Publication Types: Journal Article, Randomized Controlled Trial
- Vertical: saccharomyces-boulardii-diarrhea
Provenance
- PMID: 40457042
- DOI: 10.1038/s41598-025-04986-2
- PMCID: PMC12130261
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09